Stock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal

Stock Track

05/19

PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.

The surge appears driven by the company's recently announced strategic commercialization partnership with Tengrui Pharmaceutical for the exclusive rights to commercialize Paidakang (Weipeinatide injection), PegBio's innovative GLP-1 receptor agonist, in mainland China. The agreement sets a core target of achieving cumulative sales exceeding RMB 10 billion, with Tengrui Pharmaceutical to make an equity payment of approximately HK$140 million to PegBio. Furthermore, Tengrui has signed a strategic cooperation with Fangzhou Jianke to launch Paidakang on its internet hospital platform for a nationwide debut, expanding the drug's market access.

Analysts have noted that PegBio's valuation could see further upside potential, considering this commercialization deal alongside the potential future approval of its drug PegBin for the functional cure of chronic hepatitis B and expansion in its growth hormone business.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1148340759"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148340759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148340759?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148340759","market":"sg","top_or_hot":-1,"title":"Stock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal","media":"Stock Track","content":"<p>PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.</p><p>The surge appears driven by the company's recently announced strategic commercialization partnership with Tengrui Pharmaceutical for the exclusive rights to commercialize Paidakang (Weipeinatide injection), PegBio's innovative GLP-1 receptor agonist, in mainland China. The agreement sets a core target of achieving cumulative sales exceeding RMB 10 billion, with Tengrui Pharmaceutical to make an equity payment of approximately HK$140 million to PegBio. Furthermore, Tengrui has signed a strategic cooperation with Fangzhou Jianke to launch Paidakang on its internet hospital platform for a nationwide debut, expanding the drug's market access.</p><p>Analysts have noted that PegBio's valuation could see further upside potential, considering this commercialization deal alongside the potential future approval of its drug PegBin for the functional cure of chronic hepatitis B and expansion in its growth hormone business.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-19 10:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.</p><p>The surge appears driven by the company's recently announced strategic commercialization partnership with Tengrui Pharmaceutical for the exclusive rights to commercialize Paidakang (Weipeinatide injection), PegBio's innovative GLP-1 receptor agonist, in mainland China. The agreement sets a core target of achieving cumulative sales exceeding RMB 10 billion, with Tengrui Pharmaceutical to make an equity payment of approximately HK$140 million to PegBio. Furthermore, Tengrui has signed a strategic cooperation with Fangzhou Jianke to launch Paidakang on its internet hospital platform for a nationwide debut, expanding the drug's market access.</p><p>Analysts have noted that PegBio's valuation could see further upside potential, considering this commercialization deal alongside the potential future approval of its drug PegBin for the functional cure of chronic hepatitis B and expansion in its growth hormone business.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物醫藥-B","start_time":0,"source_url":"","article_id":"1148340759","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148340759","pubTimestamp":1779157296,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.The surge appears driven by the company's recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"个股追踪|PegBio盘中大涨28.96%独家GLP-1药物商业化交易","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PegBio Co-B's stock soared 28.96% during intraday trading on Tuesday, marking a significant price movement for the biopharmaceutical company.The surge appears driven by the company's recently announced strategic commercialization partnership with Tengrui Pharmaceutical for the exclusive rights to commercialize Paidakang (Weipeinatide injection), PegBio's innovative GLP-1 receptor agonist, in mainland China. The agreement sets a core target of achieving cumulative sales exceeding RMB 10 billion, with Tengrui Pharmaceutical to make an equity payment of approximately HK$140 million to PegBio. Furthermore, Tengrui has signed a strategic cooperation with Fangzhou Jianke to launch Paidakang on its internet hospital platform for a nationwide debut, expanding the drug's market access.Analysts have noted that PegBio's valuation could see further upside potential, considering this commercialization deal alongside the potential future approval of its drug PegBin for the functional cure of chronic hepatitis B and expansion in its growth hormone business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}